Effectiveness and safety of adjunctive antidepressants in the treatment of bipolar depression: a review.
The treatment of the depressed phase of Bipolar Disorder (BPD) is understudied and poses a widespread clinical dilemma. While the use of mood stabilizers in BPD is a common practice, the role of antidepressants in the depressive phase of the illness remains controversial. This paper reviews the available literature on the subject and highlights the factors essential for making clinical decisions for treating BPD. Most of the standard randomized controlled trials report the efficacy of antidepressants in the acute phase of BPD, but the data also indicate higher switch rates to mania and acceleration of mood cycle with their use. Nevertheless, a recent large effectiveness study (STEP-BD) found no superiority or risk of adjunct antidepressants to a mood stabilizer in the treatment of BPD. In light of the available data, future large clinical studies are essential for elucidating the role of antidepressants in the treatment of the depressed phase of BPD. Until then, factors such as history of severe manias, past depression severity and length and rapid cycling will continue to play a role in the decision of clinicians in prescribing antidepressants for BPD in different phases of the disorder.
Harel
Eiran Vadim
EV
Emotion-Cognition Research Center, The Shalvata Mental Health Care Center, Hod Hasharon, Israel.
Levkovitz
Yechiel
Y
D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans
D000928:Antidepressive Agents; D014150:Antipsychotic Agents